Last reviewed · How we verify
Traditional anticoagulation
Traditional anticoagulation is a Anticoagulant Small molecule drug developed by University of Sao Paulo General Hospital. It is currently FDA-approved for Atrial fibrillation for stroke prevention, Venous thromboembolism (DVT/PE) treatment and prophylaxis, Mechanical heart valve thromboprophylaxis. Also known as: Warfarin.
Traditional anticoagulation prevents blood clot formation by inhibiting coagulation cascade factors, typically through vitamin K antagonism or direct thrombin/factor Xa inhibition.
Traditional anticoagulation involves the use of medications such as rivaroxaban, which is an oligosaccharide modality, to prevent blood clot formation. It is studied in various conditions including peripheral arterial disease, stable and unstable angina, and is also used in combination with antithrombotic therapy.
At a glance
| Generic name | Traditional anticoagulation |
|---|---|
| Also known as | Warfarin |
| Sponsor | University of Sao Paulo General Hospital |
| Drug class | Anticoagulant |
| Target | Vitamin K-dependent coagulation factors (II, VII, IX, X) or thrombin/Factor Xa |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Traditional anticoagulants work by interfering with the body's natural blood clotting cascade. Warfarin (a vitamin K antagonist) inhibits factors II, VII, IX, and X, while older parenteral agents like heparin inhibit thrombin and factor Xa directly. These mechanisms reduce the ability of blood to form pathological clots while maintaining hemostasis.
Approved indications
- Atrial fibrillation for stroke prevention
- Venous thromboembolism (DVT/PE) treatment and prophylaxis
- Mechanical heart valve thromboprophylaxis
- Acute coronary syndrome
Common side effects
- Bleeding (major and minor)
- Bruising
- Gastrointestinal bleeding
- Intracranial hemorrhage
- Warfarin necrosis (with warfarin)
Key clinical trials
- Shared Decision Making to Address Racial Disparities in Oral Anticoagulation in NVAF (NA)
- Mechanical Thrombectomy for Acute Lower Limb Deep Vein Thrombosis in Tumor Patients (NA)
- Dynamic Change of Coronary Artery Curvature (NA)
- Nomogram for Predicting In-stent Stenosis After Pipeline Embolization Device Treatment in Patients with Intracranial Aneurysm
- Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves (PHASE4)
- Hyperbaric on Pulmonary Functions in Post Covid -19 Patients. (NA)
- Integrated Rehabilitation in Treating Post-stroke Anxiety (NA)
- Integrated Rehabilitation in Treating Post-stroke Depression (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Traditional anticoagulation CI brief — competitive landscape report
- Traditional anticoagulation updates RSS · CI watch RSS
- University of Sao Paulo General Hospital portfolio CI
Frequently asked questions about Traditional anticoagulation
What is Traditional anticoagulation?
How does Traditional anticoagulation work?
What is Traditional anticoagulation used for?
Who makes Traditional anticoagulation?
Is Traditional anticoagulation also known as anything else?
What drug class is Traditional anticoagulation in?
What development phase is Traditional anticoagulation in?
What are the side effects of Traditional anticoagulation?
What does Traditional anticoagulation target?
Related
- Drug class: All Anticoagulant drugs
- Target: All drugs targeting Vitamin K-dependent coagulation factors (II, VII, IX, X) or thrombin/Factor Xa
- Manufacturer: University of Sao Paulo General Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Atrial fibrillation for stroke prevention
- Indication: Drugs for Venous thromboembolism (DVT/PE) treatment and prophylaxis
- Indication: Drugs for Mechanical heart valve thromboprophylaxis
- Also known as: Warfarin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing